Zheng Quan Shi Bao·2025-05-11 04:49Group 1 - Over 170 stocks received initial attention from institutions this week, with 56 institutions issuing a total of 1551 "buy" ratings covering 877 stocks, a significant increase compared to the pre-holiday period [2][8] - Among the stocks, 10 with a market capitalization exceeding 100 billion yuan received focus from five or more institutions, indicating strong institutional interest in large-cap stocks [2][5] Group 2 - The pharmaceutical and biotechnology sector saw the highest number of stocks, with 100 stocks under coverage, followed by the electronics and power equipment sectors, each with over 50 stocks [3] - Recent policies from multiple government departments aim to enhance the digital transformation of the pharmaceutical industry, focusing on coordinated development and smart regulation, which is expected to drive investment in innovative drugs [3] Group 3 - Notable stocks receiving significant attention include Mindray Medical and Kweichow Moutai, each receiving "buy" ratings from nine institutions, while other companies like Shenguan Medical and Shanxi Fenjiu received seven ratings [4][5] - Kweichow Moutai is projected to achieve over 5 billion yuan in overseas revenue for 2024, with a target price set at 2205.63 yuan, suggesting a potential upside of nearly 40% [5] Group 4 - Companies like Gree Electric and Sailun Tire have announced share buyback plans, with Gree's buyback amounting to a minimum of 10.5 billion yuan, reflecting confidence in their stock performance [11][12] - Sailun Tire's net profit for 2024 is expected to increase by over 30%, indicating strong financial performance despite a recent stock price decline [12][13]